Weimin Wang
CEO
Sanegene Bio
Sanegene Bio develops a proprietary RNA interference (RNAi) drug discovery platform, LEAD™, which enables precise delivery of RNAi therapeutics to liver and extrahepatic tissues. The platform addresses unmet clinical needs across various therapeutic areas, including cardiovascular, metabolic, and immunology-related diseases.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$80MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many diseases lack effective treatments due to the difficulty of delivering drugs precisely to the affected tissues, especially outside of the liver. Traditional drug development approaches often struggle to address diseases in areas such as the cardiovascular system, the nervous system, and those related to immunology.
Solution
Sanegene Bio is developing RNA interference (RNAi) therapeutics using its proprietary LEAD™ platform to enable precise and efficient drug delivery to both liver and extrahepatic tissues. The LEAD™ platform utilizes advanced GalNAc technology for targeted delivery to the liver, and a separate platform for delivery to tissues beyond the liver. By leveraging RNAi mechanisms, Sanegene Bio aims to silence disease-causing genes, offering potential treatments for a range of conditions. Their approach focuses on advancing RNAi therapeutics to address unmet clinical needs across various therapeutic areas. The company's pipeline includes treatments for cardiovascular and metabolic diseases, immunology-related diseases, and nervous system diseases.
Target Audience
Sanegene Bio's primary target audience includes patients suffering from cardiovascular, metabolic, immunology-related, and nervous system diseases, as well as pharmaceutical companies seeking innovative drug delivery platforms.
Features
- LEAD™ GalNAc platform for targeted and efficient delivery of RNAi drugs to liver tissue.
- LEAD™ platform for extrahepatic delivery, extending the reach of RNAi medicines beyond the liver.
- RNAi therapeutics that silence disease-causing genes.
- Pipeline of RNAi therapeutics for cardiovascular and metabolic diseases.
- Pipeline of RNAi therapeutics for immunology-related diseases.
- Pipeline of RNAi therapeutics for nervous system diseases.